Association of polymorphic markers in the genes of congenital immunity receptors with the development and severity of COVID-19 clinical course

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Novel coronavirus infection (COVID-19), caused by the SARS-CoV-2 virus, has become widespread worldwide. It has been shown that receptors of congenital immunity (in particular, NOD-like receptors and RIG-I-like receptors) play an important role in the immunopathogenesis of this disease. They are able to influence the expression of cytokines and interferons genes, mediating the triggering of congenital immune responses to a pathogen. However, to date, the genetic aspects of these receptors have been studied not enough.

The aim of the study is to search and analyze the associations of polymorphic markers rs2075822 in the NOD1 gene, rs3135499 and rs8057341 in the NOD2 gene, as well as rs1990760 in the IFIH1 gene with the development and severity of COVID-19 disease.

Materials and methods. To perform the study, venous blood was taken from patients with different degrees of severity of the course of COVID-19, as well as from healthy individuals. DNA was isolated from the obtained samples, after which DNA was analyzed using the real-time polymerase chain reaction (RT-PCR) method for selected polymorphic markers.

Results. We found that markers rs3135499 and rs8057341 are associated with the incidence of coronavirus infection. Moreover, markers rs1990760 and rs2075822 are associated with a mild course of infection, while rs8057341 is associated with a course of moderate severity.

Conclusion. Obtained could be used as predictive markers in prognosticating the severity of the course of coronavirus infection in healthy individuals with an unfavorable anamnesis and a tendency to pulmonary diseases, as well as for early detection of patients predisposed to a severe course of COVID-19 among all patients with already developed clinical manifestations of the disease.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Natalia Kalyuzhnaya

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Хат алмасуға жауапты Автор.
Email: nat_kalyuzhnaya@mail.ru
ORCID iD: 0000-0002-1668-1846

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Ресей, 15 1st Dubrovskaya Str,115088, Moscow

Ekaterina Meremyanina

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: ekaterina@meremianina.ru
ORCID iD: 0000-0003-4334-1473

PhD in Medical Sciences, researcher at the Laboratory of molecular immunology, I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia, senior lecturer at the Department of virology, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Ресей, 15 1st Dubrovskaya Str,115088, Moscow; 19/38 Belomorskaya Str. 125445, Moscow

Natalya Abramova

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Email: and960911@gmail.com
ORCID iD: 0000-0002-7307-0515

junior researcher at the Laboratory of molecular immunology, I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Ресей, 15 1st Dubrovskaya Str,115088, Moscow

Elena Malinnikova

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: malinacgb@mail.ru
ORCID iD: 0000-0002-5501-5707

MD, associate professor, head of the Department of virology, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Ресей, 15 1st Dubrovskaya Str,115088, Moscow

Anna Safonova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Healthcare of Russia

Email: apotapova97@mail.ru
ORCID iD: 0009-0000-6927-1966

resident of N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Healthcare of Russia

Ресей, 24 Kashirskoe Lane,115478, Moscow

Alexander Chuchalin

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: pulmomoskva@mail.ru
ORCID iD: 0000-0002-6808-5528

MD, professor, academician of RAS, head of the Department of hospital therapy of the Faculty of pediatrics, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Chairman of the Board of the Russian Respiratory Society

Ресей, 11st Parkovaya Str., 105077, Moscow

Oksana Svitich

I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Email: svitichoa@yandex.ru
ORCID iD: 0000-0003-1757-8389

MD, professor of RAS, corresponding member of RAS, professor of the Department of microbiology, virology and immunology named after academician A.A. Vorobyov of F.F. Erisman Institute of Public Health of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), director of I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Ресей, 5A Maly Kazenny Lane, 105064, Moscow; Moscow

Әдебиет тізімі

  1. Yildirim Z., Sahin O.S., Yazar S., Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19. Cell Biol Int. 2021; 45(6): 1158–74. https://dx.doi.org/10.1002/cbin.11572.
  2. Абрамова Н.Д., Ахматова Н.К., Бишева И.В. с соавт. Мукозальный иммунитет у пациентов с COVID-19: лечение и реабилитация. Под ред. Костинова М.П., Свитича О.А., Чучалина А.Г. М.: Группа МДВ. 2022; с. 9–40. [Abramova N.D., Akhmatova N.K., Bisheva I.V. et al. Mucosal immunity in patients with COVID-19: Treatment and rehabilitation. Ed. by Kostinov M.P., Svitich O.A., Chuchalin A.G. Moscow: MDV Group. 2022; pp. 9–40 (In Russ.)]. ISBN: 978-5-906748-20-1. EDN: DEFAVJ.
  3. Арзуманян В.Г., Быстрицкая Е.П., Колыганова Т.И. с соавт. Антимикробная активность сыворотки крови до и после вакцинации препаратом «ЭпиВакКорона». Бюллетень экспериментальной биологии и медицины. 2022; 173(3): 350–356. [Arzumanyan V.G., Bystritskaya E.P., Kolyganova T.I. et al. Antimicrobial activity of serum before and after vaccination with «EpiVacCorona». Byulleten’ eksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2022; 173(3): 350–356 (In Russ.)]. https://dx.doi.org/10.47056/0365-9615-2022-173-3-350-356. EDN: WDGCGI.
  4. Khan S., Shafiei M.S., Longoria C. et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. ELife. 2021; 10: e68563. https://dx.doi.org/10.7554/eLife.68563.
  5. Watanabe T., Kitani A., Murray P.J., Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004; 5(8): 800–8. https://dx.doi.org/10.1038/ni1092.
  6. Al-Shobaili H.A., Ahmed A.A., Alnomair N.N. et al. Alnomair molecular genetic of atopic dermatitis: An update. Int J Health Sci (Qassim). 2016; 10(1): 96–120.
  7. Loos B.G., Fiebig A., Nothnagel M. et al. NOD1 gene polymorphisms in relation to aggressive periodontitis. Innate Immun. 2009; 15(4): 225–32. https://dx.doi.org/10.1177/1753425909103739.
  8. Huebner C., Ferguson L.R., Han D.Y. et al. Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: A case-control study. BMC Res Notes. 2009; 2: 52. https://dx.doi.org/10.1186/1756-0500-2-52.
  9. Pan H., Dai Y., Tang S., Wang J. Polymorphisms of NOD2 and the risk of tuberculosis: A validation study in the Chinese population. Int J Immunogenet. 2012; 39(3): 233–40. https://dx.doi.org/10.1111/j.1744-313X.2011.01079.x.
  10. Leturiondo A.L., Noronha A.B., Mendonça C.Y.R. et al. Association of NOD2 and IFNG single nucleotide polymorphisms with leprosy in the amazon ethnic admixed population. PLOS Negl Trop Dis. 2020; 14(5): e0008247. https://dx.doi.org/10.1371/journal.pntd.0008247.
  11. Xiong J.H., Mao C., Sha X.W. et al. Association between genetic variants in NOD2, C13orf31, and CCDC122 genes and leprosy among the Chinese Yi population. Int J Dermatol. 2016; 55(1): 65–69. https://dx.doi.org/10.1111/ijd.12981.
  12. Li L., Yu H., Jiang Y. et al. Genetic variations of NLR family genes in Behcet’s disease. Sci Rep. 2016; 6: 20098. https://dx.doi.org/10.1038/srep20098.
  13. Liu S., Wang H., Jin Y. et al. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Geneti. 2009; 18(2): 358–65. https://dx.doi.org/10.1093/hmg/ddn342.
  14. Zurawek M., Fichna M., Januszkiewicz D. et al. Polymorphisms in the interferon-induced helicase (IFIH1) locus and susceptibility to Addison’s disease. Clin Endocrinol (Oxf). 2013; 78(2): 191–96. https://dx.doi.org/10.1111/j.1365-2265.2012.04497.x.
  15. Rydzewska M., Goralczyk A., Goscik J. et al. Analysis of chosen polymorphisms rs2476601 a/G–PTPN22, rs1990760 C/T–IFIH1, rs179247 a/G–TSHR in pathogenesis of autoimmune thyroid diseases in children. Autoimmunity. 2018; 51(4): 183–190. https://dx.doi.org/10.1080/08916934.2018.1486824.
  16. Leite F.R.M., Enevold C., Bendtzen K. et al. Pattern recognition receptor polymorphisms in early periodontitis. J Periodontol. 2019; 90(6): 647–54. https://dx.doi.org/10.1002/JPER.18-0547.
  17. Smyth D.J., Cooper J.D., Bailey R. et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet. 2006; 38(6): 617–19. https://dx.doi.org/10.1038/ng1800.
  18. Sutherland A., Davies J., Owen C.J. et al. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves’ disease susceptibility. J Clin Endocrinol Metab. 2020; 92(8): 3338–41. https://dx.doi.org/10.1210/jc.2007-0173.
  19. Enevold C., Kjaer L., Nielsen C.H. et al. Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes. Rheumatol Int. 2014; 34(10): 1401–8. https://dx.doi.org/10.1007/s00296-014-3012-4

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>